Sökning: "small intestine neuroendocrine tumors"
Visar resultat 1 - 5 av 7 avhandlingar innehållade orden small intestine neuroendocrine tumors.
1. Profiling of Small Intestine Neuroendocrine Tumors
Sammanfattning : Small intestine neuroendocrine tumors (SI-NETs) are malignant neoplasms usually presenting with disseminated disease and symptoms of hormone overproduction. Radical surgery is curative but can only be performed for localized disease. For most patients the disease follows a progressive and fatal course. LÄS MER
2. Novel Circulating and Tissue Biomarkers for Small Intestine Neuroendocrine Tumors and Lung Carcinoids
Sammanfattning : Small intestine neuroendocrine tumors (SI-NETs) and lung carcinoids (LCs) are relatively indolent tumors, which originate from neuroendocrine (NE) cells of the diffuse NE system. Metastases can spread before diagnosis. Thus, potential cures become unavailable, which entitles new biomarker development. LÄS MER
3. Vesicle proteins as markers for neuroendocrine tumors
Sammanfattning : The neuroendocrine (NE) tumours comprise a diversity of tumours which share commonproperties, e.g. the capacity to produce, store and release hormones. A prominent feature ofthe NE phenotype is the production of secretory granules with associated vescicle proteins,e. LÄS MER
4. lmprovement of 177Lu-octreotate treatment of small-intestine neuroendocrine tumors by hyperfractionation
Sammanfattning : Neuroendocrine tumor incidence is steadily rising, and the late diagnosis often results in metastatic disease and current treatments mostly prolong life and in-crease quality of life without increasing cure rate. 177Lu-octreotate was recently approved for treatment of neuroendocrine tumors, but the dosage scheme should be optimized. LÄS MER
5. Lutetium-177-octreotate treatment of small intestine neuroendocrine tumors - Radiation biology as basis for optimization
Sammanfattning : Patients with neuroendocrine tumors (NETs) often have metastatic spread at the time of diagnosis. NETs frequently express somatostatin receptors (SSTR) that can be targeted by radiolabeled somatostatin analogs (e.g. 177Lu-octreotate). LÄS MER